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Abstract
Background: Analysis of 23 published transcriptome studies allowed us to identify nine genes
displaying frequent alterations in HNSCC (FN1, MMP1, PLAU, SPARC, IL1RN, KRT4, KRT13, MAL, and
TGM3). We aimed to independently confirm these dysregulations and to identify potential
relationships with clinical data for diagnostic, staging and prognostic purposes either at the tissue
level or in saliva rinse.
Methods: For a period of two years, we systematically collected tumor tissue, normal matched
mucosa and saliva of patients diagnosed with primary untreated HNSCC. Expression levels of the
nine genes of interest were measured by RT-qPCR in tumor and healthy matched mucosa from 46
patients. MMP1 expression level was measured by RT-qPCR in the salivary rinse of 51 HNSCC
patients and 18 control cases.
Results: Dysregulation of the nine genes was confirmed by the Wilcoxon test. IL1RN, MAL and
MMP1 were the most efficient diagnostic markers of HNSCC, with ROC AUC > 0.95 and both
sensitivity and specificity above 91%. No clinically relevant correlation was found between gene
expression level in tumor and T stage, N stage, tumor grade, global survival or disease-free survival.
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Our preliminary results suggests that with 100% specificity, MMP1 detection in saliva rinse is
potentially useful for non invasive diagnosis of HNSCC of the oral cavity or oropharynx, but
technical improvement is needed since sensitivity was only 20%.
Conclusion: IL1RN, MAL and MMP1 are prospective tumor diagnostic markers for HNSCC.
MMP1 overexpression is the most promising marker, and its detection could help identify tumor
cells in tissue or saliva.
Background
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common malignancy worldwide and every
year an estimated 600,000 people are newly diagnosed.
HNSCC accounts for about 10% of the total cancer bur-
den in men [1]. It is often diagnosed at late stages in heavy
alcohol and tobacco users and patients presenting
advanced disease have a short overall survival with major
post-therapeutic side effects. Despite ongoing efforts, no
molecular markers have yet been validated as useful clin-
ical tools for the early detection and management of this
disease. Recently, the transcriptome of HNSCC was exten-
sively probed by several groups using expression microar-
ray technology. The goals were to identify the genes
potentially involved in this pathology and to identify
diagnostic and/or prognostic gene-expression signatures
[2-27]. Although the heterogeneous designs of these stud-
ies (number of sample, tumor sites, tumor stages, micro-
dissection of tissue samples, RNA extraction and RT
protocols, microarray technologies or biostatistics analy-
ses) probably explain the diversity of the results, there is
nevertheless strong motivation to develop robust molecu-
lar diagnostic tests [28].
We reviewed 23 studies published between March 2000
and November 2007, in which expression profiles of
HNSCC tumors versus their normal matched mucosa
were compared. Despite the important methodological
heterogeneity of gene expression studies 9 genes appeared
to be repeatedly dysregulated, in at least nine of the 23
studies for each gene [2-27]. Four genes were up-regulated
in HNSCC tissues (FN1, MMP1, PLAU and SPARC) and
five were down-regulated (IL1RN, KRT4, KRT13, MAL and
TGM3). Because these genes were recurrently found to be
dysregulated whatever the tumor location and despite the
important methodological heterogeneity of the gene
expression studies, we hypothesized that these nine genes
could be candidate as HNSCC-specific molecular markers.
We therefore evaluated by RT-qPCR their expression level
in 46 HNSCC samples and 46 healthy matched mucosa
taken from an independent cohort of 74 patients consec-
utively diagnosed with primary untreated HNSCC in our
institution. We assessed their tumor diagnostic values and
looked at possible correlations with clinical data. The
need for early detection in high-risk patients led several
groups to develop techniques for identifying molecular
markers in bodily fluid rather than in an invasive biopsy
unsuitable for cancer screening. Saliva is an easily accessi-
ble diagnostic fluid for screening HNSCC [29]. In this
study, we assessed the capacity of MMP1, one of the most
relevant markers, to detect HNSCC tumor cells in saliva
cells; this provided information on its utility as a non
invasive diagnostic marker.
Methods
Patients and sample collection
All normal and tumor tissues, as well as saliva samples,
were obtained from the Institutional Tumor Bank of the
University Hospital of Nîmes, France. All samples were
collected with the informed consent of the patients. This
study was approved by the local ethics committee and the
scientific board of the Tumor Bank.
Tumor tissue, normal matched mucosa and saliva were
obtained from 74 patients consecutively diagnosed with
primary untreated HNSCC between April 2005 and April
2007 in our institution. All HNSCC patients were Cauca-
sian heavy smokers and drinkers. Additional saliva sam-
ples from 18 healthy controls were collected, between
February and April 2008. This cohort of control cases was
composed of two populations: 9 consecutive patients ref-
ereed to our institution by their physician for HNSCC
screening, motivated by heavy drinking and smoking
addictions; 9 consecutive patients without alcohol or
tobacco addiction in their past history that consulted for
otologic or rhinologic mechanical disorders. All patients
underwent a head and neck examination to determine the
absence or presence of HNSCC and to rule out any signif-
icant inflammatory lesion of the upper aero-digestive
tract. Patients in the control group were statistically a little
younger and with more women than in the HNSCC group
(average age = 52.8 years for controls vs 58.8 years for
HNSCC [p = 0.037, student test]; sex ratio = 0.38 for con-
trols vs 0.11 for HNSCC [p = 0.029 2-sample test for
equality of proportions]).
Tissue samples were collected by biopsy during diagnostic
endoscopy and were immediately snap frozen and stored
in liquid nitrogen. The matched non-malignant tissue was
collected from the same anatomical site, as far as possible
from the primary lesion for tumors crossing the midline
or on the opposite side for well-lateralized tumors.BMC Cancer 2009, 9:370 http://www.biomedcentral.com/1471-2407/9/370
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For saliva collection both HNSCC patients and control
cases followed the same protocole. Subjects were asked to
refrain from eating, drinking, smoking, or oral hygiene
procedures for at least 1 hour before collection and carried
out a 30-second oral rinse with 50 ml of NaCl 0.9% solu-
tion that was immediately centrifuged at 2600 rpm for 15
minutes at 4°C. The supernatant was discarded and the
pellet was diluted into 1 ml of NaCl 0.9% and stored at -
80°C before RNA extraction. The clinical and histopatho-
logical features of the populations are presented in Table
1.
RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-charac-
terized samples for RNA analyses, tissue samples were cut
with a cryo-microtome into 50-200 slices of 9-μm thick-
ness in RNase-free conditions. At least three frozen slices
taken from the sample core were mounted on glass slides
and briefly stained with eosin-hematoxylin for his-
topathological examination by an experienced patholo-
gist (H.C.). Tumor tissue versus normal surrounding
tissue percentage (T/N %) was determined for malignant
samples. HNSCC samples with less than 30% tumor cells
were excluded from the study. Tissue samples were not
microdissected in order to include in the qPCR analysis
not only the tumor cells, but also the surrounding stromal
cells, which are known to have altered transcriptional
activity during the carcinogenetic process [30]. Normal
tissues had to be composed of both stroma and its sur-
rounding normal epithelial layer, without any tumor
cells, to be included in the study. Total RNA was extracted
from the remaining tissue slices using the RNeasy Mini Kit
(Qiagen, Courtaboeuf, France). Saliva rinse RNA extrac-
tion was carried out using the RNA Isolation Kit on a
Table 1: Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations
Table 1-A Table 1-B
Tissu samples (n = 46) Saliva samples: Control population (n = 18)
Median Min Max Median Min Max
Age 56.7 41.2 77.7 Age 53 32 71
Qt % Qt %
Sex Woman 48 . 7 Sex Woman 63 3 . 3
Men 42 91.3 Men 12 66.6
Site Larynx 81 7 . 4
Oral cavity 81 7 . 4 Saliva samples: HNSCC population (n = 51)
Hypopharynx 71 5 . 2 Median Min Max
Oropharynx 23 50 Age 59 41 83
T Stage 1 12 . 2 Qt %
2 11 23.9 Sex Woman 61 1 . 8
3 19 41.3 Men 45 88.2
4 15 32,6
N Stage 0 18 39.1 Site Larynx 59 . 8
1 48 . 7 Oral cavity 11 21.7
2 23 50 Hypopharynx 81 5 . 7
3 12 . 2 Oropharynx 27 52.8
M Stage 0 46 100 T Stage 1 61 1 . 8
1 00 2 12 23.5
3 14 27.4
Grade 1 13 28.3 4 19 37.3
2 27 58.7
3 61 3N Stage 0 17 33.2
+ 34 66.7
Death Yes 21 45.7
No 25 54.3 M Stage 0 50 1.9
1 19 8 . 1
Follow-up Controlled 25 54.3
Progression 10 21.7
Recurrence 11 23.9
Qt: quantity
%: percentageBMC Cancer 2009, 9:370 http://www.biomedcentral.com/1471-2407/9/370
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MagNa Pure Compact instrument (Roche, Meylan,
France).
RNA quality control and quantification were carried out
on an Agilent 2100 Bioanalyser using Total RNA Nano II
Chips (Agilent Technologies, Massy, France). To limit the
impact of possible RNA degradation on our results, we
selected for further analysis, only tissue samples with total
RNA concentrations >85 ng/μl and values of RNA integ-
rity number (RIN) >6. and saliva samples with total RNA
concentration >40 ng/μl and RIN value >4. These criteria
were never responsible of sample removal as satisfying
qualities could be obtained by a second or third extraction
procedure when required.
After quality control of tissues and saliva of the initial
cohort of 74 HNSCC patients, 46 matched pairs of tumor
tissue and normal mucosa and 51 saliva samples were
useful. For 23 patients we analyzed both tissues and
saliva. For 23 patients we analysed tissues only and for 28
patients saliva only. From our initial cohort of 74 HNSCC
patients, 46 matched pairs of tumor tissue and normal
mucosa as well as 51 saliva samples were useful. The
amount of tissue, either tumor or normal mucosa, was
insufficient for 28 patients to carry out pathological anal-
ysis and mRNA extraction. Saliva collection missed for 18
patients and saliva collection procedures were inadequate
for 5 other patients. Finally only 23 patients were ana-
lyzed both at the tissue and saliva level. No relation was
found between sample removal and tumor stage.
After quality control, 1 μg of total RNA was reverse tran-
scribed using M-MLV reverse transcriptase and oligo dT14-
16 primers (Applied Biosystems, Courtaboeuf, France).
Samples were incubated for 10 minutes at 65°C, cooled
on ice for 5 minutes, and incubated with reverse tran-
scriptase for 1 hour at 37°C. Reverse transcriptase was
then inactivated by heating at 95°C for 5 minutes. The
resulting cDNA were diluted 1:10 for tissue samples and
1:4 for saliva samples before being used as PCR template.
Quantitative real-time PCR (qPCR
We quantified the mRNA expression of three housekeep-
ing genes and the nine genes of interest by real-time RT-
qPCR using the Light Cycler Fast DNA Masterplus SYBR
green kit on LightCycler 480 (Roche, Meylan, France).
Stringent primers sets were designed using Oligo 6 Soft-
ware (MBI, Cascade, CO, USA). To avoid false detection of
genomic DNA, although DNase was used for the extrac-
tion procedure, amplification was done on spliced regions
of the genes. Gene references and primer characteristics
are listed in Table 2. For each qPCR reaction we used 2 μl
of the diluted cDNA, 1 μl of 10 μmol.l-1 forward primer, 1
μl of 10 μmol.l-1 reverse primer, 5 μl Light Cycler Fast
DNA Masterplus SYBR green I and 11 μl PCR water, for a
final volume of 20 μl. The PCR cycle conditions were set
as follow: a preincubation step for 10 minutes at 95°C fol-
lowed by 40 cycles for tissue cDNA and 53 cycles for saliva
cell cDNA; each cycle included 15 seconds at 95°C, 15
seconds at 60°C, and 15 seconds at 72°C. The tempera-
ture transition rate was 20°C/second. A melting curve was
generated by linear heating from 50°C to 95°C in 20 min-
utes with 10 fluorescence measures every 1°C. A negative
control, with no template, and a positive inter-run control
were included for each gene in each qPCR run. All meas-
urements were performed in triplicate. Standard curve
assays showed an efficient amplification >1.8 for all genes
and the specificity was shown by a single peak at the
expected temperature on melting curve analyses (Table 2).
For each gene the inter-assay coefficient of variation of
crossing point values was <10% (data not shown).
For the salivary assay, 50 cycles of the above-described
qPCR procedure were carried out in order to detect very
low concentrations of mRNA. As this number of cycle was
extremely high in order to detect very low concentration
of mRNA, the PCR specificity was controlled with care by
melting curve analysis of the PCR products and by nega-
tive controls. Whatever, the highest Cp value observed
was 44.2 cycles. The whole RT-qPCR procedure was car-
ried out with and without RT enzyme, confirming the
absence of contamination by genomic DNA during the
automated saliva rinse RNA extraction process (data not
shown).
qPCR data analysis
values were automatically calculated by LightCycler 480®
Software using the second derivative method and were
imported into qBase, version 1.3.5, a free software pro-
gram for the management and automated analysis of
qPCR data, for quantitative analyses [31]. Normal tissue
cDNA of patient 5 was arbitrarily chosen as a calibrator for
each gene, and for this sample the expression level was set
at 1 for each gene. For each gene qPCR amplification effi-
ciencies were calculated by qBase from standard curves
and were applied in the quantification algorithm. Relative
quantities were normalized by qBase to a geometric mean
of the three housekeeping genes ACT, B2M and RPS18.
Concerning the housekeeping gene set stability assess-
ment, raw relative quantities were tested with geNorm
software, version 3.4, for the combination of the three
genes. geNorm algorithm calculates a gene expression sta-
bility measure M for a reference gene based on the average
pairwise variation for that gene with all other tested refer-
ence genes [32].
Statistical analysis
S-Plus 2000 software (TIBCO Software, Inc., Palo Alto,
CA, USA) was used to perform the statistical analyses. The
quantitative variables were described by median, mini-BMC Cancer 2009, 9:370 http://www.biomedcentral.com/1471-2407/9/370
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mum and maximum values and the qualitative variables
were described by frequencies and percentages. Genetic
markers were compared between HNSCC tissues and
matched normal mucosa using a Wilcoxon test for paired
data. Comparisons were considered significant when p <
0.05.
The ability of each gene to diagnose the tumor tissue
(HNSCC diagnostic ability) was represented by a Receiver
Operating Characteristic (ROC) curve and the corre-
sponding Area Under the Curve (AUC). The ROC curves
and AUC were assessed by a non-parametric method [33].
The optimal cut-off used to calculate both sensitivity and
specificity, was defined as the cut-off minimizing the
number of misclassified tissues.
The clinical relevance of HNSCC markers was analyzed by
correlating the expression level and clinical-pathological
parameters. For each gene, the expression level in HNSCC
was compared according to stage T, stage N, histological
grade and tumor tissue versus normal surrounding tissue
percentage (T/N %) using a Kruskal-Wallis test. The Cox
model was used to analyze global survival and disease-
free survival. For survival tests, the median follow-up was
1 year and 3 months.
Since no data were available concerning the diagnosis val-
ues of our candidate markers, it was not possible to deter-
mine a statistically based number of sample. Then, we
decided to include all patients with exploitable samples,
available at our Institutional Tumor Bank at the time of
analysis.
Results
Housekeeping gene stability
To date there is no published evidence to guide the selec-
tion of suitable housekeeping genes for the normalization
of HNSCC RT-qPCR studies. Hence, we chose to normal-
ize our qPCR relative ratio by the geometric mean of three
commonly used housekeeping genes in cancer studies:
ACT, B2M and RPS18. We validated this approach using
geNorm software, version 3.4, which gave an expression
stability measure based on the average pairwise variation
of the three genes [32]. In our assay the stability value (M)
of the association of ACT, B2M and RPS18 was M = 1.2.
This M value, below the 1.5 arbitrary cut-off recom-
Table 2: Characteristics of the gene-specific qPCR assays
Gene name (synonym) Access n° Gene ID Gene location Primer sequence 5'-3' Amplicon size Melting 
T°c
PCR efficiency
KRT4 NM_002272 12q12-q13 f: tcaacaacaagtttgcctc 185 1.94
keratin 4 3851 r: gtcattgcccaaggtatcta 90
IL1RN NM_173841 2q14.2 f: cctgtcctgtgtcaagtctg 257 1.80
interleukin 1 receptor 
antagonist
3557 r: cgtcctcctggaagtagaat 90
KRT13 NM_153490 17q12-q21.2 f: tctctgtcttgctggtctga 234 1.88
keratin 13 3860 r: atgaagaggagatgaaggaa 89
MMP1 NM_002421 11q22.3 f: aaagacagattctacatgcg 237 1.92
matrix metallopeptidase 1 4312 r: tgcttcacagttctaggga 85
PLAU NM_002658 10q24 f: ggactacatcgtctacctgg 230 1.90
plasminogen activator, 
urokinase
5328 r: caaactggggatcgttatac 88
SPARC NM_003118 5q31.3-q32 f: ggtgactgaggtatctgtgg 245 1.85
secreted protein acidic 
cysteie-rich
6678 r: aggtcttgttgtcattgctg 90
TGM3 NM_003245 20q11.2 f: cactctccaatggcagtagt 215 1.93
transglutaminase 3 7053 r: cataaagacgctatccacat 88
FN1 NM_212482 2q34 f: tgacacttatgagcgtcct 234 1.81
fibronectin 1 2335 r: aaacacttctcagctatggg 86
MAL NM_002371 2cen-q13 f: ataaagccgcagtagaactt 181 1.95
mal, T-cell differentiation 
protein
4118 r: agagtaaacacagcacccac 84
ACTB NM_001101 7p15-p12 f: tggctggggtgttgaaggtct 238 1,89
actin, beta 60 r: agcacggcatcgtcaccaact 90
B2M NM_004048 15q21-q22.2 f: cagcgtactccaaagattca 240 1.99
beta-2-microglobulin 567 r: gaatgctccactttttcaat 90
RPS18 NM_022551 6p21.3 f: agcttgttgtccagaccatt 187 1.84
ribosomal protein S18 6222 r: tgaggaaagcagacattgac 87
T°c: TemperatureBMC Cancer 2009, 9:370 http://www.biomedcentral.com/1471-2407/9/370
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mended by the software, means that our set of three
housekeeping genes was appropriate for normalization.
Differential gene expression between HNSCC and normal 
matched mucosa
Normalized relative expression levels of the nine selected
genes were calculated by qBase for each sample. These
expression levels were compared between HNSCC and
normal matched tissues for the 46 patients (92 samples).
As presented in Table 3, relative mRNA expression levels
were significantly higher in tumor than in healthy sam-
ples for FN1, MMP1, PLAU and SPARC (Wilcoxon test for
paired data, p ≤ 0.002). These levels were lower in tumor
than in normal samples for KRT4, KRT13, IL1RN, MAL
and TGM3 (Wilcoxon test for paired data, p < 0.001). For
each gene, the median expression level ratio between
tumor tissues and their matched normal mucosa are pre-
sented in Figure 1. Among the overexpressed genes in
tumor, MMP1  showed the highest order of magnitude
(510-fold) and FN1 the lowest (2.6-fold). Among down-
regulated genes in tumor, KRT4 showed the highest order
of magnitude (530-fold) and IL1RN the lowest (9-fold).
HNSCC diagnostic ability of the nine genes
The ability of the nine selected genes to diagnose HNSCC
was assessed by generating ROC curves. Corresponding
AUC were calculated for each gene in order to find the best
single marker to differentiate between normal mucosa
and HNSCC tissue. Apart from FN1, which showed a poor
AUC value (0.693), all genes demonstrated good diagnos-
tic abilities with AUC > 0.86. Three genes were considered
remarkable (IL1RN, MAL and MMP1) with AUC > 0.95.
As presented in Table 4, when optimized cut-off values
were selected, the single expression level of IL1RN, MAL
or MMP1 correctly predicted the tumor or normal nature
of tissue samples in, respectively, 87, 86 and 88 cases out
of the 92 tested samples. Corresponding sensitivities
ranged from 93.7 to 95.7% and specificities ranged from
91.3 to 97.8%. Interestingly, the association of these three
genes in a multivariate model did not enhance diagnostic
efficacy (data not shown). For each gene detailed statistics
are listed in Table 4 (AUC of ROC curves, cut-off values
and corresponding sensitivity, specificity, true positive
value, false positive value, true negative value and false
negative value).
Clinical relevance of the nine genes
We investigated a possible association between the expres-
sion levels of the nine genes measured in tumor and T
stage, N stage and histological grade. No statistical differ-
ence was found between expression levels in tumor of
patients with stage N0 versus stage N+. The p-values
ranged from 0.26 to 0.98 except for KTR4  (p = 0.08,
Kruskal-Wallis test). Statistical differences were found
between patients with histological grade 1 versus grade 2-
3 for IL1RN (p = 0.01) and SPARC (p = 0.03). For the
other genes, p-values ranged from 0.27 to 0.99. Statistical
differences were found between patients with stage T2 ver-
sus stage T3-T4 for SPARC (p = 0.01). For the other genes,
p-values ranged from 0.11 to 0.96.
A univariate survival analysis did not detect genes signifi-
cantly correlated to global survival. For three genes, haz-
ard ratios (HR) were low but with large confidence
intervals: TGM3 (HR = 0.23 [0.02-2.94]), MAL (HR = 0.23
[0.02-2.24]) and IL1RN (HR = 0.38 [0.06-2.46]). Similar
results were found when disease-free survival was ana-
lyzed.
MMP1 mRNA detection in salivary rinse
Among the three best markers for HNSCC at the diagnos-
tic level, MMP1 was the only one to be overexpressed in
tumors. We hypothesized that its expression could be
detected in the saliva rinses of patients with HNSCC,
where tumor cells are known to desquamate. We carried
out a preliminary assay to tested this gene in saliva but not
the other 8 candidate genes. Among the 51 HNSCC
patients, only 10 (20%) exhibited MMP1  mRNA at a
Table 3: Expression levels of the 9 genes of interest in HNSCC and normal matched mucosa
Normal Tissue HNSCC Tissue
Gene median St Dev min max median St Dev min max p-values
FN1 0.076 0.280 0.004 1.577 0.268 0.471 0.007 2.185 0.002
IL1RN 1.801 1.851 0.304 9.149 0.204 0.304 0.010 1.675 <0.001
KTR13 9.110 105.525 0.217 564.113 0.156 5.193 <0.001 28.358 <0.001
KTR4 2.647 75.657 0.080 479.146 0.004 1.120 <0.001 6.003 <0.001
MAL 2.319 3.378 0.262 19.968 0.033 0.266 <0.001 1.182 <0.001
MMP1 0.755 7.395 0.033 43.727 319.480 1515.1 3.038 7510.565 <0.001
PLAU 0.995 15.426 0.304 105.707 6.831 18.192 0.274 109.053 <0.001
SPARC 0.302 0.198 0.065 1.000 0.985 0.996 0.140 4.791 <0.001
TGM3 1.399 17.775 0.064 121.378 0.035 13.594 0.001 92.326 <0.001
The median, minimum and maximum values of relative normalized ratios for each gene of interest in normal tissue versus HNSCC tissue, with 
corresponding p-value (Wilcoxon test for paired data).BMC Cancer 2009, 9:370 http://www.biomedcentral.com/1471-2407/9/370
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measurable concentration in their saliva rinse. For these
positive samples, MMP1 signal was detected at a mean Cp
value of 36.4 cycles (31.7-44.2). As presented table 5,
among the 10 HNSCC tumors detected by MMP1 salivary
test, six aroused from the oropharynx, 3 from the oral cav-
ity and 1 from the hypopharynx. MMP1 expression level
in tissues was available for 3 out of the 10 patients with
MMP1 positives salivary rinse. These three patients had
1000-fold overexpression of MMP1 in HNSCC comparing
to normal matched mucosa. No MMP1 signal was detect-
able in the control group of 18 patients. ACT, B2M and
RPS18 were used as positive internal control in this assay.
Contrary to MMP1, their mRNA expression was detectable
in all saliva samples at mean Cp values of 27.7, 28.8 and
31.7 cycles for ACT, B2M and RPS18, respectively.
Discussion
Transcriptome profiling of tumor is a promising approach
to identifying gene dysregulations potentially useful at the
clinical level to detect or diagnose tumors and predict out-
come, as well as to identify the gene pathways involved in
carcinogenic processes. In the field of HNSCC, numerous
studies have been performed but all have failed to find
clinical applications, essentially because of the great diver-
sity in their designs and the lack of a confirmatory step in
an independent cohort of patients [2-27]. When we
looked closely at the HNSCC transcriptome analyses
some genes emerged as frequently dysregulated and there-
fore as specific candidates as HNSCC molecular markers.
This original study is the first to validate independently
the gene dysregulation observed in various HNSCC tran-
Differential mRNA expression of the nine genes of interest in macroscopically healthy mucosa and HNSCC tissue Figure 1
Differential mRNA expression of the nine genes of interest in macroscopically healthy mucosa and HNSCC tis-
sue. For estimation of the individual expression of each gene, the expression ratios of paired tissue specimens were calculated 
as R = HNSCC/normal. The distribution of the log of these ratios is represented for each gene by a box-plot. The central box 
represents the interquartile interval, the white line inside the box is the median value, and the minimum and the maximum val-
ues are indicated with square brackets.BMC Cancer 2009, 9:370 http://www.biomedcentral.com/1471-2407/9/370
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scriptome assays. Our study, based on RT-qPCR analysis,
is not a definitive transcriptome validation assay, but it
clearly proves that reliable biological information with
potential clinical applications, can be obtained by pool-
ing the results of several transcriptome data despite heter-
ogeneous designs and small patient cohorts.
Using this gene selection and validation approach, we
identified eight efficient transcriptional markers to predict
the presence of HNSCC cells in tissue samples, with three
remarkable markers: IL1RN, MAL and  MMP1. When
tested individually, these three markers presented specifi-
city above 91% and sensitivity above 93% in a cohort of
46 patients with various stages, grades and sites of the dis-
ease. Surprisingly, there was no additional gain when
these three top markers were evaluated together in a mul-
tivariate model rather than each separately. This finding
implies that above 90% of both specificity and sensitivity
little additional information can be expected by associat-
ing several transcriptional markers. It also indicates that
the biological information associated with these three
dysregulated genes should be somehow similar as far as
diagnosis is concerned. It is worth mentioning that in clin-
ical routine the use of only one well-characterized diag-
nostic marker has the advantage of being simple.
No clinically relevant correlations were identified
between gene expression level measured in tumor and
clinical or pathological parameters. This absence of corre-
lation could signify that these dysregulations are common
early events in HNSCC carcinogenesis, making these
genes useful as diagnostic markers but useless as staging or
prognostic markers. The proportion of early-stage tumor
was low in our population, with 12 stage T2 tumors
(26%); nonetheless, these nine dysregulations remained
statistically significant in this subgroup of patient. This
finding confirmed that these markers could be used for
the detection of early-stage as well as later-stage tumors.
Among these three most remarkable dysregulated genes
for HNSCC diagnosis, MMP1 was highly overexpressed.
We thus hypothesized that it could be detected in the
saliva rinses of patients with HNSCC for diagnosis or
screening purposes. Indeed, several studies recently
focused on the detection of such cells, mainly by studying
DNA alterations (e.g., mutation, hypermethylation) but
also by RNA detection [34]. Through a transcriptome sal-
ivary approach, Li et al. identified a set of seven overex-
pressed genes in saliva from patients presenting oral
squamous cell carcinoma; their association in a multivar-
iate model yielded a sensitivity of 91% and a specificity of
91% [35-40]. Li et al used the cell-free saliva for their tran-
scriptome study. On the contrary, we choose to extract
RNA from salivary floating-cells. In our opinion mRNA
overexpression due to tumour alterations is more likely to
be detected in the salivary floating-cells pellets than in the
more RNA-diluted free cell saliva. Kim et al reported an
elevation of MMP1 in saliva related to refractory perio-
dontitis in microarray study of oral subepithelial connec-
tive tissues [41]. We do not think that periodontal health
changes were responsible of MMP1 elevation in saliva of
our patients since no clear differences of periodontal sta-
tus were noticed between HNSCC patients and control
Table 4: Diagnostic values of the 9 gene of interest
Gene AUC Cut-off value False negative False positive True negative True positive Sensitivity (%) Specificity (%)
FN1 0,693 0.20 19 11 35 27 58.7 76.1
IL1NR 0,974 0.51 3 2 44 43 93.5 95.7
KTR13 0,921 4.80 1 11 33 42 75.0 95.5
KTR4 0,947 0.23 5 4 42 41 89.1 91.3
MAL 0,986 0.72 2 4 42 44 95.7 91.3
MMP1 0,989 24.00 3 1 45 43 93.5 97.8
PLAU 0,897 2.30 9 5 41 37 80.5 89.1
SPARC 0,864 0.67 13 3 43 33 71.7 93.5
TGM3 0,939 0.31 7 4 42 39 84.8 91.3
Calculation of AUC values for the relative expression levels of the nine genes of interest by ROC analyses and the corresponding diagnostic values 
with optimum cut-off value.
Table 5: Characteristics of patients with positive MMP1 salivary 
test
Patient Tumor site T stage N stage M stage
1 Oral cavity 100
2 Oral cavity 4a 2b 0
3 Oral cavity 4a 2c 0
4 Oropharynx 200
5 Oropharynx 22 b0
6 Oropharynx 32 b0
7 Oropharynx 4a 0 0
8 Oropharynx 4a 2c 0
9 Oropharynx 4a 2c 1
10 Hypopharynx 32 b0
Tumor sites and TNM stages of the 10 patients with detectable levels 
of MMP1 in their saliva rinse.BMC Cancer 2009, 9:370 http://www.biomedcentral.com/1471-2407/9/370
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cases or between MMP1  positive and MMP1  negative
HNSCC patients.
As most of the patients likely to develop HNSCC are reluc-
tant to consult physicians when the first symptoms occur,
a noninvasive screening method based on the detection of
tumor cells among epithelial oral cells could be of inter-
est. In this preliminary salivary study, we confirmed that
the expression of MMP1 was confined to HNSCC tumor
cells as no expression was detected within the healthy
population. Unfortunately, the sensitivity was low as only
20% of the patients presenting the disease were detected.
Given that the salivary donors in our study presented
advanced tumors, mostly symptomatic or easily detecta-
ble by standard clinical examination, this salivary
approach could be considered as inefficient. On the other
hand, the 100% specificity seems encouraging and
HNSCC screening by a non-invasive salivary/oral screen-
ing test remains a promising field of research. In our
study, the lack of sensitivity to detect salivary expression
of MMP1 could have been due to suboptimal procedures
for saliva collection, RNA extraction and retro-transcrip-
tion. Sensitized procedures would increase the quantity of
tumor cells and mRNA in samples and therefore improve
the sensitivity of this technique [29].
The nine dysregulated genes have very different biological
functions and some of them are already known to be
implicated in cancer. From a clinical point of view, IL1RN,
MAL and TGM3 were not clearly identified as potential
HNSCC markers, while few data have been published
concerning the implication of FN1, KRT, MMP1, PLAU
and SPARC in this type of cancer. From a fundamental
point of view, further studies are required to assess the
functional mechanisms implicated in the dysregulations
we observed.
Conclusion
We confirmed in an independent study the dysregulation
of FN1, MMP1, PLAU SPARC, IL1RN, KRT4, KRT13, MAL
and TGM3 in HNSCC. Three of them, MMP1, MAL and
IL1RN, were remarkable at identifying HNSCC in compar-
ison with normal mucosa. They thus present an interest-
ing potential as screening/diagnostic markers, still to be
evaluated at the clinical level. MMP1 was the most prom-
ising gene of this study because it was overexpressed in
tumor, highly dyregulated (500-fold) and tumor-specific.
In addition to salivary detection, MMP1 could be tested at
the RNA level for its ability to identify small tumor clus-
ters in diagnostic biopsies, surgical margins or lymph
nodes in the setting of primary tumors. This would be a
valuable complement to histopathological analyses
which efficacy for the diagnosis of microscopic tumors is
low.
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